For several decades, a century-old vaccine has been used to treat a specific type of bladder cancer. In the 1970s, the Bacillus Calmette-Guérin (BCG) vaccine was approved as an immunotherapeutic treatment for bladder cancer patients.
Since then, various BCG vaccines have become the standard therapy for treating high-risk nonmuscle-invasive bladder cancer (NMIBC) patients to prevent the recurrence and progression of the disease.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
